Medrx Co., Ltd. AI Stock Analysis
Want to see JP:4586 full AI Analyst Report?
Medrx Co., Ltd. (4586) AI Stock Analysis
Medrx Co., Ltd.
(TSE/TYO:4586)
The score is primarily constrained by ongoing losses and negative cash generation, with additional pressure from weak medium- and long-term technical trends and a negative P/E ratio. Revenue growth and zero debt provide meaningful but insufficient support.
Medrx Co., Ltd. (4586) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 3.49B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.06M
- Price to Earnings (P/E)
- -3.6
- Beta (1Y)
- 1.41
- Revenue Growth
- -81.42%
- EPS Growth
- 36.56%
- Country
- Japan
- Employees
- 21
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Medrx Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal absorption syste...
How the Company Makes Money
Medrx primarily makes money by monetizing its transdermal drug delivery technologies and related pharmaceutical products. Key revenue streams typically include: (1) licensing/out-licensing of developed transdermal formulations or drug candidates to p...
Medrx Co., Ltd. Financial Statement Overview
Summary
Revenue growth and a debt-free balance sheet are strengths, but persistent net losses, deeply negative operating cash flow, and weak capital efficiency materially reduce the score.
Income Statement
35NegativeBalance Sheet
75PositiveCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 121.00M | 128.08M | 257.92M | 29.53M | 59.48M | 8.35M |
| Gross Profit | 109.78M | 113.01M | 219.19M | -18.43M | 10.45M | -54.25M |
| EBITDA | -868.59M | -928.13M | -754.62M | -888.00M | -1.05B | -1.00B |
| Net Income | -858.85M | -937.37M | -806.76M | -932.90M | -1.11B | -1.06B |
Balance Sheet | ||||||
| Total Assets | 1.74B | 2.16B | 2.27B | 2.05B | 1.40B | 2.11B |
| Cash, Cash Equivalents and Short-Term Investments | 1.14B | 1.75B | 1.98B | 1.72B | 994.02M | 1.70B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 149.79M | 108.54M | 107.00M | 127.52M | 185.56M | 153.10M |
| Stockholders Equity | 1.59B | 2.05B | 2.17B | 1.92B | 1.21B | 1.96B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -970.86M | -803.00M | -913.76M | -1.08B | -926.23M |
| Operating Cash Flow | 0 | -888.11M | -803.00M | -913.00M | -1.07B | -923.69M |
| Investing Cash Flow | 0 | -82.75M | -3.15M | -759.00K | -1.96M | -2.54M |
| Financing Cash Flow | 0 | 745.09M | 1.07B | 1.64B | 356.31M | 815.91M |
Medrx Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4586, the sentiment is Neutral. The current price of 47.00 is above the 20-day moving average (MA) of 44.60, below the 50-day MA of 53.00, and below the 200-day MA of 73.48, indicating a neutral trend. The MACD of -3.69 indicates Negative momentum. The RSI at 56.83 is Neutral, neither overbought nor oversold. The STOCH value of 51.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4586.
Medrx Co., Ltd. Peers Comparison
Overall Rating
JP:458248Neutral
JP:453946.5Neutral
JP:458643Neutral
JP:488343Neutral
JP:489242Neutral
JP:459739Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | JPY 7.16B | -0.82 | ― | ― | -30.58% | 6.93% | |
| 47Neutral | JPY 5.57B | -11.41 | ― | 3.24% | 0.31% | -194.72% | |
| 43Neutral | JPY 3.71B | -3.58 | ― | ― | -81.42% | 36.56% | |
| 43Neutral | JPY 3.73B | -1.41 | ― | ― | ― | 25.34% | |
| 42Neutral | JPY 5.08B | -6.53 | ― | ― | 214.65% | 22.18% | |
| 39Underperform | JPY 6.55B | -7.89 | -53.06% | ― | 109.82% | 61.98% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4586 | Medrx Co., Ltd. | 47.00 | -75.00 | -61.48% | |
| JP:4597 | Solasia Pharma KK | 24.00 | -7.00 | -22.58% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1543.00 | 68.97 | 4.68% | |
| JP:4582 | Symbio Pharmaceuticals Limited | 71.00 | -33.00 | -31.73% | |
| JP:4883 | Modalis Therapeutics Corporation | 31.00 | -36.00 | -53.73% | |
| JP:4892 | Cyfuse Biomedical K.K. | 515.00 | -69.00 | -11.82% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 18, 2026
